#USA #Paris #10x Genomics #Broad Clinical Labs #Bioptimus

Bioptimus Introduces STELA: The Epicenter of Spatial Biology

On March 25, 2026, Bioptimus, a pioneering AI biotech company, announced an ambitious initiative, STELA (Spatial Tissue Embedding Learning Atlas), which aims to establish the world's largest multimodal atlas for spatial biology. This initiative is a collaborative effort with notable partners, including 10x Genomics and Broad Clinical Labs, and it seeks to revolutionize how patient data is integrated and utilized in the fields of oncology and immunology.

The Vision Behind STELA

Bioptimus's goal with STELA is clear: profile an unprecedented 100,000 patient specimens. This endeavor represents a significant scaling, roughly 20 times more than existing spatial biology atlases. At its core, STELA aims to create harmonized multi-omics patient data that will significantly enhance our understanding of biological processes and disease mechanisms.

The initiative is particularly focused on laying the groundwork for M-Optimus, the first world model of biology. By providing a comprehensive data backbone, STELA will allow researchers to unlock insights about human tissues, contributing to advancements in personalized medicine and therapeutic development. Jean Philippe Vert, the Co-Founder and CEO of Bioptimus, articulated this aim, emphasizing the potential for patient data to inform future treatment protocols beyond the individual, creating a rich, interconnected dataset that spans diverse patient demographics and disease states.

Partnering with Industry Leaders

The collaboration with 10x Genomics is crucial as it leverages the Xenium spatial transcriptomics platform as a foundational tool to generate robust, reproducible datasets. This partnership signifies a new era in data generation methodology, where spatial biology technologies meet large-scale AI model development. Serge Saxonov, CEO and Co-founder of 10x Genomics, highlighted the initiative's potential to reshape biomedical data usage, connecting intricate biological interactions with clinical outcomes.

Simultaneously, Bioptimus has secured a multi-year strategic partnership with Broad Clinical Labs. This collaboration focuses on producing spatial biology data en masse, using Broad's high-throughput capabilities to process biological samples. Niall Lennon, Chief Scientific Officer at Broad Clinical Labs, stressed the importance of pairing high-scale data generation with rigorous quality controls to ensure data integrity, ensuring that the results obtained from STELA can be confidently translated into clinical practices.

An Unprecedented Data Resource

STELA is set to integrate a multitude of data modalities, including high-resolution spatial transcriptomics, matched histopathology images, and other omics data, along with longitudinal clinical records—essentially creating a comprehensive database of patient information. This integration aims to not only improve diagnostic precision but also sharpen therapeutic strategies across oncology and immunology, potentially leading to faster drug developments and better patient outcomes.

Participating hospitals and research institutions will benefit from STELA's standardized protocols while providing their specimens, making it a mutually beneficial arrangement. The knowledge gathered from this endeavor will help clinicians convert vast amounts of data into actionable clinical insights. Bioptimus's drive to establish a cohesive data generation framework promises to deliver the necessary infrastructure to foster the next era of biological AI.

Looking Forward

As STELA unfolds over the coming years, it has the potential to create a lasting impact across multiple realms of medicine and research. The collaboration between Bioptimus, 10x Genomics, and Broad Clinical Labs is more than a mere partnership; it represents a shift toward a synergized approach in exploring the intricate tapestry of human biology. This global initiative not only lights the path for future innovations in precision medicine but also empowers researchers and healthcare providers to anticipate and respond to the complexities of human disease with newfound clarity.

In summary, by bridging the gap between large-scale data generation and AI applications in biology, STELA is positioned to become a defining resource for researchers striving to understand the complexities of diseases and to pave the way for groundbreaking therapeutic advancements.